Table 1.
Laboratory analysis
| Parameter | Value | Reference range |
|---|---|---|
| Laboratory profile at admission | ||
| White-cell count, n × 1,000/uL | 18.41 | 4.80–10.90 |
| Differental count | ||
| Neutrophils, % | 78.9 | 45–75 |
| Lymphocytes, % | 14.1 | 20–50 |
| Hemoglobin, g/dL | 8.4 | 13.3–17.7 |
| Platelet count, n × 1,000/uL | 484 | 150–400 |
| Alanine aminotransferase, U/L | 1,459 | 5–41 |
| Aspartate aminotransferase, U/L | 562 | 5–40 |
| Creatinine, mg/dL | 2.07 | 0.70–1.30 |
| EGFR, mL/min/1.73 m2 | 24 | >60 |
| Glucose, mg/dL | 629 | 74–106 |
| β-hydroxybutiric acid, mmol/L | 1.2 | 0.02–0.27 |
| Hemoglobin A1c, % | 10.2 | 4.0–6.4 |
| Lactate, venous, mmol/L | 10.51 | 0.5–1.6 |
| Prothrombin time, s | 16.7 | 10–13 |
| Activated partial thromboplastin time, s | 33.4 | 26.6–36.5 |
| Fibrinogen, mg/dL | 1,196 | 250–490 |
| D-dimer, ng/mL | 6,197 | 0–229 |
| Serum ferritin, ng/mL | 504 | 13–150 |
| C-reactive protein, mg/dL | 38.98 | 0.03–0.49 |
| Lactate dehydrogenase, U/L | 1,250 | 135–225 |
| pH (venous) | 6.68 | 7.35–7.45 |
| pCO2 (venous), mm Hg | 35 | 41–51 |
| pO2 (venous), mm Hg | 37 | 25–40 |
| SARS-CoV-2 RT-PCR | Detected | Not detected |
| Timeline of additional studies | ||
| Hospital day 10a | ||
| Anticardiolipin antibody IgG (GPL) | 119 | <14 |
| Anticardiolipin antibody IgM (MPL) | 59 | <12 |
| Anticardiolipin antibody IgA (APL) | <11 | <11 |
| Anti-β2-glycoprotein-I IgG, IgM, IgA (SGU, SMU, SAU) | <9 | <9 |
| Hospital day 13a | ||
| C3 complement, mg/dL | 171 | 90–180 |
| C4 complement, mg/dL | 40 | 10–40 |
| Hospital day 14a | ||
| Activated partial thromboplastin time, s | 49.8 | 26.6–36.5 |
| Lupus anticoagulant PTT screen, s | 49 | <40 |
| Thrombin clotting time, s | 19 | 13–19 |
| Dilute Russell viper venom time, s | 28 | <45 |
| Lupus anticoagulant hexagonal phase confirmation | Weak positive | Negative |
| Protease-3 antibody, AU/mL | 2.3 | <1.0 |
| Myeloperoxidase antibody, AU/mL | 0 | <1.0 |
| Hospital day 17a | ||
| C3 complement, mg/dL | 154 | 90–180 |
| C4 complement, mg/dL | 41.7 | 10–40 |
| Complement CH50, CAE units | 120 | 60–144 |
| Hospital day 18 | ||
| SARS-CoV-2 RT-PCR | Detected | Not detected |
| Activated partial thromboplastin time, s | 39.8 | 26.6–36.5 |
| Lupus anticoagulant PTT screen, s | 40 | 32–48 |
| Dilute Russell viper venom time, s | 29 | 22–44 |
| Anticardiolipin antibody IgG (GPL) | 80 | <14 |
| Anticardiolipin antibody IgM (MPL) | 19 | <12 |
| Anticardiolipin antibody IgA (APL) | 6.6 | <11 |
| Anti-β2-glycoprotein-I IgG, IgM, IgA (SGU, SMU, SAU) | <9 | <9 |
| Hospital day 19a | ||
| Protease-3 antibody, AU/mL | 132 | <1.0 |
| Myeloperoxidase antibody, AU/mL | 0 | <1.0 |
| Hospital day 20a | ||
| C3 complement, mg/dL | 155 | 90–180 |
| C4 complement, mg/dL | 46.9 | 10–40 |
| C8 complement, mg/dL | 14.8 | 10.7–24.9 |
| C9 complement, mg/dL | 41 | 6.0–29.0 |
| Hospital day 33b,c | ||
| SARS-CoV-2 RT-PCR | Detected | Not detected |
| Hospital day 34c | ||
| COVID-19 antibody assay | Positive | Negative |
| Hospital day 38c | ||
| Anticardiolipin antibody IgG (GPL) | 40 | <14 |
| Anticardiolipin antibody IgM (MPL) | 9.6 | <12 |
| Anticardiolipin antibody IgA (APL) | 4.1 | <11 |
| Anti-β2-glycoprotein-I IgG, IgM, IgA (SGU, SMU, SAU) | <9 | <9 |
| Protease-3 antibody, AU/mL | 73 | <1.0 |
| Myeloperoxidase antibody, AU/mL | 1 | <1.0 |
| Hospital day 40c | ||
| SARS-CoV-2 RT-PCR | Detected | Not detected |
| Hospital day 46c | ||
| Dilute Russell viper venom time screen, ratio | 1.2 | <1.2 |
| Lupus anticoagulant silica clotting time screen, ratio | 1.0 | <1.2 |
| Anticardiolipin antibody IgG (GPL) | 20.9 | <14 |
| Anticardiolipin antibody IgM (MPL) | 7.5 | <12 |
| Anticardiolipin antibody IgA (APL) | 9.0 | <11 |
| Anti-β2-glycoprotein-I IgG, IgM, IgA (SGU, SMU, SAU) | <9 | <9 |
| Hospital day 47c | ||
| SARS-CoV-2 RT-PCR | Indeterminate | Not detected |
| Hospital day 49c | ||
| SARS-CoV-2 RT-PCR | Not detected | Not detected |
| Hospital day 50c | ||
| SARS-CoV-2 RT-PCR | Not detected | Not detected |
a
Patient on continuous heparin infusion.
b
Patient on continuous argatroban Infusion.
c
Patient on oral warfarin.